Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib

Medicine and Dentistry

• Chronic Myelogenous Leukemia 100%
• Imatinib 100%
• Leukemia Cell 100%
• Activin A 100%
• Programmed Cell Death 28%
• p38 Mitogen-Activated Protein Kinase 28%
• Growth Inhibition 28%
• Multidrug Resistance 14%
• Glycophorin A 14%
• Procaspase 3 14%
• Disease 7%
• Cell Differentiation 7%
• Short Hairpin RNA 7%
• SB 203580 7%
• Group Therapy 7%
• Bcl-xL 7%
• Poly ADP Ribose Polymerase 7%
• BCR ABL Protein 7%
• Progenitor Cell Line 7%
• RNA Knockdown 7%
• Cytotoxicity 7%
• Progenitor Cell 7%
• Transforming Growth Factor 7%

Biochemistry, Genetics and Molecular Biology

• Imatinib 100%
• Activin 100%
• Myeloid 100%
• P38 Mitogen-Activated Protein Kinases 28%
• Growth Inhibition 28%
• Multidrug Resistance 14%
• Glycophorin 14%
• Progenitor Cell 14%
• Cellular Differentiation 7%
• Bcl-xL 7%
• RNA Knockdown 7%
• SB 203580 7%
• Cytotoxicity 7%
• Small Hairpin RNA 7%
• Transforming Growth Factor 7%
• Poly ADP Ribose Polymerase 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Myeloid Leukemia 100%
• Activin A 100%
• Imatinib 100%
• Multiple Drug Resistance 14%
• Procaspase 3 14%
• Glycophorin A 14%
• Cytotoxicity 7%
• Short Hairpin RNA 7%
• Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase 7%
• SB 203580 7%
• BCR ABL Protein 7%
• Disease 7%
• Transforming Growth Factor 7%